<em>Background</em>: The aim of this study was to test Viusid and Asbrip as adjuvants to the standard treatment of patients with COVID-19 disease which could favor the recovery of the patients and reduce t...<em>Background</em>: The aim of this study was to test Viusid and Asbrip as adjuvants to the standard treatment of patients with COVID-19 disease which could favor the recovery of the patients and reduce the hospitalization days.<em> Design</em>: This is a randomized, open-label, controlled trial to determine the efficacy and safety of Viusid and Asbrip in hospitalized patients with mild to moderate symptoms of COVID-19. <em>Material and Methods</em>: A total of 60 patients with proven COVID-19 disease by PCR test were randomized in a 2:1 ratio. In the active group 40 patients received oral doses of Viusid (30 ml TID) and Asbrip (10 ml TID) plus standard treatment. The control group consisted of 20 patients receiving only standard treatment. The trial began with hospitalization, followed by home treatment for a total of 21 days. Four symptoms were followed: fever, dyspnea, cough and fatigue, assessed by score 0 - 3: 0 = well, 1 = mild, 2 = moderate, 3 = severe, with total sum, Composite Symptom Score (CSS) from 0 to 12. <em>Results</em>: The 21 days diagram of CSS shows statistically better results of Viusid-Asbrip group vs. Control group from day 4 to day 21. Time to semi-recovery in days, assessed by 50% of CSS, is better in Viusid-Asbrip group vs. Control group (6.07 ± 2.77 vs. 8.35 ± 2.94, p = 0.02). Time to recovery in days respectively is (14.05 ± 4.15 vs. 19.25 ± 2.12, p = 0.0001). And Hospitalization days are (9.05 ± 2.58 vs. 12.75 ± 4.44, p = 0.0003). <em>Conclusion</em>: This trial shows that adding of Viusid & Asbrip to the treatment of COVID-19 can contribute to faster recovery of the patients, decreasing of the hospital stay and milder course of the disease.展开更多
For given datawe study constrained interpolation problem of Favard typewhere dx is the arc length of f in [0,1]. We prove the existence of a solution f, of the above problem, that is a quadratic spline with a second d...For given datawe study constrained interpolation problem of Favard typewhere dx is the arc length of f in [0,1]. We prove the existence of a solution f, of the above problem, that is a quadratic spline with a second derivative f, . which coincides with one of the constants between every two consecutive knots. Thus, we extend a result of Karlin concerning Favard problem, to the case of restricted length interpolation.展开更多
Let be a hypercube in Rn. We prove theorems concerning mean-values of harmonic and polyharmonic functions on In(r), which can be considered as natural analogues of the famous Gauss surface and volume mean-value formul...Let be a hypercube in Rn. We prove theorems concerning mean-values of harmonic and polyharmonic functions on In(r), which can be considered as natural analogues of the famous Gauss surface and volume mean-value formulas for harmonic functions on the ball in and their extensions for polyharmonic functions. We also discuss an application of these formulas—the problem of best canonical one-sided L1-approximation by harmonic functions on In(r).展开更多
文摘<em>Background</em>: The aim of this study was to test Viusid and Asbrip as adjuvants to the standard treatment of patients with COVID-19 disease which could favor the recovery of the patients and reduce the hospitalization days.<em> Design</em>: This is a randomized, open-label, controlled trial to determine the efficacy and safety of Viusid and Asbrip in hospitalized patients with mild to moderate symptoms of COVID-19. <em>Material and Methods</em>: A total of 60 patients with proven COVID-19 disease by PCR test were randomized in a 2:1 ratio. In the active group 40 patients received oral doses of Viusid (30 ml TID) and Asbrip (10 ml TID) plus standard treatment. The control group consisted of 20 patients receiving only standard treatment. The trial began with hospitalization, followed by home treatment for a total of 21 days. Four symptoms were followed: fever, dyspnea, cough and fatigue, assessed by score 0 - 3: 0 = well, 1 = mild, 2 = moderate, 3 = severe, with total sum, Composite Symptom Score (CSS) from 0 to 12. <em>Results</em>: The 21 days diagram of CSS shows statistically better results of Viusid-Asbrip group vs. Control group from day 4 to day 21. Time to semi-recovery in days, assessed by 50% of CSS, is better in Viusid-Asbrip group vs. Control group (6.07 ± 2.77 vs. 8.35 ± 2.94, p = 0.02). Time to recovery in days respectively is (14.05 ± 4.15 vs. 19.25 ± 2.12, p = 0.0001). And Hospitalization days are (9.05 ± 2.58 vs. 12.75 ± 4.44, p = 0.0003). <em>Conclusion</em>: This trial shows that adding of Viusid & Asbrip to the treatment of COVID-19 can contribute to faster recovery of the patients, decreasing of the hospital stay and milder course of the disease.
基金This research was supported by the Sofia University Research Foundation under project 399/2001.
文摘For given datawe study constrained interpolation problem of Favard typewhere dx is the arc length of f in [0,1]. We prove the existence of a solution f, of the above problem, that is a quadratic spline with a second derivative f, . which coincides with one of the constants between every two consecutive knots. Thus, we extend a result of Karlin concerning Favard problem, to the case of restricted length interpolation.
文摘Let be a hypercube in Rn. We prove theorems concerning mean-values of harmonic and polyharmonic functions on In(r), which can be considered as natural analogues of the famous Gauss surface and volume mean-value formulas for harmonic functions on the ball in and their extensions for polyharmonic functions. We also discuss an application of these formulas—the problem of best canonical one-sided L1-approximation by harmonic functions on In(r).
